The $29B Cash Machine

The global deodorant market was valued at roughly $28.7 billion in 2024 and is projected to reach approximately $49.6 billion by 2033 — a compound growth rate that most SaaS companies would envy, delivered by a product that costs under $5 to manufacture.

During lockdowns, deodorant usage dropped measurably. A Mintel survey found 28% of US consumers admitted deodorising less frequently. An Ipsos UK poll from late 2020 found 14% had stopped using deodorant entirely. The US market dipped from $3.8B (2019) to $3.72B (2020) — a 2% decline in a year when offices emptied globally.

By 2022, US deodorant sales had jumped to $4.36B — higher than pre-COVID. The category didn't just recover. It leapfrogged its prior ceiling.

Between 2022 and 2024, Unilever pushed extraordinary price increases through Personal Care — and deodorants specifically delivered positive volume growth alongside double-digit pricing. In each SEC filing, deodorants are called out as the sub-category exception that held volumes while taking price.

Note the crossover: as pricing normalised from peak 13.5% down to 1.4%, volumes accelerated — from negative to mid-single digit positive. The category's demand curve is close to vertical. People don't trade down on deodorant the way they do on ice cream or laundry detergent.

Unilever is the global leader in deodorants — a €24 billion category growing by more than 6% per year. 95% of its deodorant turnover comes from just four brands. This concentration is the moat.

Mass-market products still dominate ~94% of global deodorant sales. But every high-growth sub-segment — natural, premium, whole-body, men's grooming — is growing at 1.5-2x the category average.

Dove Whole Body Deodorants retail at $11.99 versus $6.99 for standard Dove — a 71% price premium on a product with marginal cost differences. That delta drops almost directly to the bottom line.

The biggest growth lever in this category isn't price or population. It's redefining where deodorant goes. Whole-body deodorant expands the addressable surface area from ~0.03 m² (two armpits) to the full human body (~1.7 m²).

The demand signal is extraordinary: 76% of US consumers are interested in trying whole-body deodorants, while only 2% currently use them. That 74-point gap is the most attractive whitespace in personal care.

The Dr. Squatch deal is the signal. Unilever isn't buying distribution models anymore (that was Dollar Shave Club's subscription play, which they exited in 2023). They're buying product-market fit in expanding categories.

The categories growing fastest — whole-body, natural, fine fragrance — are precisely where no single function can win alone. The winners are building continuous intelligence loops between disciplines:

You can't develop a whole-body deodorant by optimising a single variable. You need the cultural insight, the experimental design, the sensory science, and the manufacturing capability. The companies that build this collective intelligence will own the next phase. The ones that don't will end up acquiring the ones that do.

The global deodorant category is a ~$29 billion market growing at ~6% annually, controlled by a concentrated oligopoly with demonstrated pricing power that survived the most extreme demand shock in living memory. It's expanding its TAM through format innovation, consumer segmentation, and channel diversification.

This isn't a sector in need of disruption. It's a sector demonstrating how a mature category — managed with discipline and informed by cross-functional intelligence — compounds value year after year. The boring bet is always the right bet.